子宫内膜样卵巢癌的综合分子图谱
本研究对26例子宫内膜样卵巢癌(EOVC)样本和15例匹配正常组织进行全外显子测序,并与子宫内膜癌(UCEC)及高级别浆液性卵巢癌(HGSC)比较。结果显示EOVC具有异质性分子特征,显著突变基因频率与UCEC相似,部分病例类似HGSC,62%病例存在潜在治疗靶点。
要点
- EOVC显著突变基因包括PTEN、CTNNB1、PIK3CA等,频率与UCEC相似
- EOVC中可见错配修复缺陷和POLE突变导致的高突变,频率与UCEC相似
- 部分EOVC病例具有TP53突变、HRd签名和广泛CNV,类似HGSC
核心结论
- EOVC是一组分子异质性的上皮性卵巢癌,具有独特的突变特征。
- 在精准肿瘤学时代,需了解少见组织学亚型的独特分子驱动因素以促进基因组驱动的治疗。
研究设计与样本
- 对26例EOVC样本和15例匹配正常组织进行全外显子测序。
- 利用基因突变、突变特征和拷贝数变异构建多维回归分类器,与UCEC和HGSC比较。
- 在独立的EOVC临床测序登记中验证发现。
主要发现
- EOVC具有独特且异质的基因组图谱。
- 显著突变基因(PTEN、CTNNB1、PIK3CA、KMT2D、KMT2B、PIK3R1、ARID1A和TP53)在EOVC中的频率与UCEC相似。
- 错配修复缺陷和POLE突变导致的高突变在EOVC中观察到的频率与UCEC相似。
- 部分EOVC病例类似UCEC,另一部分类似HGSC,后者携带TP53突变、同源重组缺陷突变特征和广泛CNV。
- 机器学习分类器证实了EOVC的异质性组成。
关键数值与推荐
- EOVC中显著突变基因包括PTEN、CTNNB1、PIK3CA、KMT2D、KMT2B、PIK3R1、ARID1A和TP53。
- 62%的EOVC病例存在潜在治疗靶点。
临床怎么用
- 对EOVC进行分子 profiling 有助于识别潜在治疗靶点,指导精准治疗。
- EOVC的分子异质性提示需结合突变特征和CNV进行综合评估。
局限性
- 样本量较小(EOVC n=26,正常 n=15)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endometrioid ovarian carcinoma (EOVC) is an uncommon subtype of epithelial ovarian carcinoma and its molecular characteristics have been incompletely described. Prior sequencing investigations have been limited to targeted gene panels. We performed whole-exome sequencing to build an unbiased genetic profile of molecular alterations in endometrioid ovarian tumors with a goal to better understand this disease in the context of epithelial ovarian cancer and endometrioid uterine cancers. METHODS: Whole-exome sequencing was performed on EOVC samples (n = 26) and matched normals (n = 15). Gene mutations, mutational signatures and copy number variations (CNVs) informed a multi-dimensional regression classifier allowing for comparison to endometrial carcinoma (UCEC) and high grade serous ovarian carcinoma (HGSC). RESULTS: EOVC has a distinct and heterogeneous genomic profile. Identified significantly mutated genes in EOVC (PTEN, CTNNB1, PIK3CA, KMT2D, KMT2B, PIK3R1, ARID1A and TP53) occurred at similar frequencies in UCEC. Hypermutation, resulting from both mismatch repair deficiency (MMRd) and POLE mutation, was observed in EOVC at a frequency similar to UCEC. Like UCEC, a subset of EOVC cases closely resembled HGSC, harboring TP53 mutations, homologous recombination deficiency (HRd) mutation signatures and widespread CNVs. A machine-learning classifier confirmed the heterogeneous composition of EOVC. Potential therapeutic targets were identified in 62% of EOVC cases. We validated our findings in an orthogonal clinical sequencing registry of EOVC cases. CONCLUSIONS: We identified that EOVC are a molecularly heterogeneous group of epithelial ovarian cancers with distinct mutational signatures. In an age of precision oncology, there is a pressing need to understand the unique molecular drivers in uncommon histologic subtypes to facilitate genomically driven oncologic treatments.
引用
- Pierson WE, Peters PN, Chang MT, et al. An integrated molecular profile of endometrioid ovarian cancer. Gynecol Oncol. 2020. PMID: 32139151. doi:10.1016/j.ygyno.2020.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。